UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia.
Journal
Therapeutic advances in medical oncology
Journal Volume
16
ISSN
1758-8340
Date Issued
2024
Author(s)
Ye, Dingwei
Kanesvaran, Ravindran
Chiong, Edmund
Lojanapiwat, Bannakij
Rawal, Sudhir Kumar
Aik, Ong Teng
Zeng, Hao
Chung, Byung Ha
Ashani, Md Yusoff Noor
Ohyama, Chikara
Kim, Choung Soo
Hu, Zhiquang
Tsai, Yuh-Shyan
Razack, Azad Hassan Abdul
Singh, Anildeep
Liu, Yanfang
Uemura, Hirotsugu
Abstract
The incidence of prostate cancer (PC) is increasing in Asian countries. The epidemiology of PC, its treatment including the use of novel therapeutic options, impacts on quality of life, and clinical outcomes of patients with PC in Asia, are not well documented. To describe the demographic and disease features of the full cohort of patients enrolled in the United in Fight against prOstate cancer (UFO) registry. The UFO registry was a multi-national, longitudinal, observational study of patients with PC presenting to participating tertiary care hospitals in eight Asian countries/regions. Patients with high-risk localized PC (HRL), non-metastatic biochemically recurrent, or metastatic PC were consecutively enrolled from September 14, 2015 until September 1, 2020 and followed for up to 5 years. Among the full cohort of 3635 patients, 425 had HRL, 389 had non-metastatic biochemically recurrent, and 2821 had metastatic PC. Median follow-up time was 4.2, 4.2, and 2.6 years, respectively. At first diagnosis, the mean age ranged from 65.7 to 69.1 years, 38.5% had extra-capsular tumor extension, 34.0% had regional lymph node metastases, and 65.1% had distant metastases. Quality-of-life scores at enrollment were significantly worse in patients with metastatic disease. Decisions to start therapy were mainly driven by treatment guidelines and disease progression. The decision to discontinue hormonal therapy was often due to disease progression. Few patients received novel hormonal therapies despite their availability. The UFO registry provides a detailed, contemporary picture of the characteristics, treatment, and outcomes of patients with PC in Asia. There is an unmet medical need to improve access to novel agents in Asia, aiming to improve quality of life and clinical outcomes. Clinicaltrials.gov Identifier: NCT02546908, Registry Identifier: NOPRODPCR4001.
Subjects
Asia
epidemiology
prostate cancer
quality of life
registry
SDGs
Type
journal article